Cybin Inc. (CYBN) Research

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Market snapshot

Symbol
CYBN
Price
$8.28
Day change
+1.22%
Market cap
$112.5M
P/E ratio
-1.59x
52-week range
4.81-10.7199
Sector
Healthcare
Industry
Biotechnology

Recent news

  • FTSE 100 Live: London stocks slide as aerospace and defence sector falls

    FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...

  • Psychedelics stocks rise after Trump order expands research, access pathways

    Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...

Peer companies

  • Alector, Inc. (ALEC)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Innate Pharma S.A. (IPHA)
  • Milestone Pharmaceuticals Inc. (MIST)
  • Molecular Partners AG (MOLN)
  • Nkarta, Inc. (NKTX)
  • PepGen Inc. (PEPG)
  • Rani Therapeutics Holdings, Inc. (RANI)

Open Cybin Inc. (CYBN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.